Ionis Pharmaceuticals (IONS) Stock Price, News & Analysis

Company Overview

Ionis Pharmaceuticals (NASDAQ:IONS), founded in 1989 and headquartered in Carlsbad, California, is a pioneer in RNA-targeted drug discovery and development. The company’s proprietary antisense technology enables the design of therapeutic agents that selectively bind to RNA to inhibit, enhance, or modulate the production of disease‐causing proteins. Over three decades of innovation have positioned Ionis as a leader in advancing novel treatments for a wide range of serious and rare diseases.

Ionis’s product portfolio includes several approved therapies developed in collaboration with global partners. Key launches include SPINRAZA (nusinersen) for spinal muscular atrophy, co-developed with Biogen, as well as Tegsedi (inotersen) and Waylivra (volanesorsen) for rare forms of transthyretin amyloidosis and familial chylomicronemia syndrome. Beyond these marketed products, Ionis maintains a robust pipeline targeting cardiovascular, metabolic, neurological and oncology indications, with numerous candidates in late-stage clinical trials.

The company operates research and development facilities across North America, Europe and Asia, and collaborates with leading pharmaceutical organizations such as Roche, AstraZeneca and Biogen. These strategic alliances enable Ionis to leverage external expertise and resources, accelerating the transition of its RNA-targeted therapies from discovery through regulatory review. Ionis’s collaborative model ensures efficient advancement of programs while retaining control over its core antisense platform.

Under the leadership of CEO Brett P. Monia, Ph.D., Ionis continues to expand its scientific capabilities and global footprint. Supported by a board of directors with extensive industry experience, the management team remains focused on translating RNA science into therapeutic solutions. Ionis is dedicated to addressing unmet medical needs and improving patient outcomes by advancing innovative treatments based on its pioneering antisense technology.

Key Stats

• Today's Range: $41.45 to $42.19
• 50-Day Range: $31.86 to $43.59
• 52-Week Range: $23.95 to $52.34
• Volume: 1.55 million shs
• Average Volume: 1.62 million shs
• Market Capitalization: $6.64 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $58.25
• Consensus Rating: Moderate Buy

Ionis Pharmaceuticals Stock Analysis - MarketRank™

Ionis Pharmaceuticals scored higher than 92% of companies evaluated by MarketBeat, and ranked 88th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Ionis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 13 buy ratings, 3 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Ionis Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Ionis Pharmaceuticals are expected to grow in the coming year, from ($3.50) to ($2.41) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ionis Pharmaceuticals is -13.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ionis Pharmaceuticals is -13.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ionis Pharmaceuticals has a P/B Ratio of 11.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.11% of the float of Ionis Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Ionis Pharmaceuticals has a short interest ratio ("days to cover") of 8.

Change versus previous month

Short interest in Ionis Pharmaceuticals has recently decreased by 0.63%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ionis Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Ionis Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.0 / 5
• Environmental Score: -3.58

Percentage of Shares Shorted

9.11% of the float of Ionis Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Ionis Pharmaceuticals has a short interest ratio ("days to cover") of 8.

Change versus previous month

Short interest in Ionis Pharmaceuticals has recently decreased by 0.63%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.18

News Sentiment

Ionis Pharmaceuticals has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Ionis Pharmaceuticals this week, compared to 8 articles on an average week.

Search Interest

Only 14 people have searched for IONS on MarketBeat in the last 30 days. This is a decrease of -7% compared to the previous 30 days.

MarketBeat Follows

2 people have added Ionis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Ionis Pharmaceuticals insiders have bought 2,377.19% more of their company's stock than they have sold. Specifically, they have bought $477,900.00 in company stock and sold $19,292.00 in company stock.

Percentage Held by Insiders

Only 2.60% of the stock of Ionis Pharmaceuticals is held by insiders.

Percentage Held by Institutions

93.86% of the stock of Ionis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IONS Stock Analysis - Frequently Asked Questions

How have IONS shares performed this year?

Ionis Pharmaceuticals' stock was trading at $34.96 at the beginning of the year. Since then, IONS stock has increased by 19.4% and is now trading at $41.73.

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced its quarterly earnings results on Wednesday, April, 30th. The company reported ($0.93) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.14. Ionis Pharmaceuticals's revenue was up 10.9% compared to the same quarter last year.
Read the conference call transcript.

Who are Ionis Pharmaceuticals' major shareholders?

Ionis Pharmaceuticals' top institutional shareholders include Sovran Advisors LLC (0.20%), Assenagon Asset Management S.A. (0.01%), Wedmont Private Capital and Parallel Advisors LLC. Insiders that own company stock include Brett P Monia, Elizabeth L Hougen, Richard S Geary, B Lynne Parshall, C Frank Bennett, Brian Birchler, Patrick R O'neil, Michael R Hayden, Eric Swayze, Eugene Schneider, Onaiza Cadoret-Manier, Joseph Baroldi, Joseph Klein III and Allene M Diaz.
View institutional ownership trends.

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ionis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ionis Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 4/30/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IONS
• CIK: 874015
• Web: www.ionispharma.com
• Phone: (760) 931-9200
• Fax: 760-603-2700
• Employees: 1,069
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Ionis Pharmaceuticals: $58.25
• High Price Target: $77.00
• Low Price Target: $37.00
• Potential Upside/Downside: +39.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$453.90 million
• Net Margins: -63.65%
• Pretax Margin: -64.65%
• Return on Equity: -91.85%
• Return on Assets: -15.77%

Debt

• Debt-to-Equity Ratio: 2.63
• Current Ratio: 9.66
• Quick Ratio: 9.62

Sales & Book Value

• Annual Sales: $705 million
• Price / Sales: 9.42
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.73 per share
• Price / Book: 11.19

Miscellaneous

• Outstanding Shares: 159,160,000
• Free Float: 155,021,000
• Market Cap: $6.64 billion
• Optionable: Optionable
• Beta: 0.23